UMass Medical School pharmacy experts will present posters on adherence to regimens for chronic hepatitis C, the impact of prescriber outreach on co-prescribing opioids with other medications and the effect of a federal schedule change on prescribing hydrocodone combination drugs at the annual meeting of the Academy of Managed Care Pharmacy (AMCP) April 19-22 at Moscone West in San Francisco.
A poster that has been awarded the bronze medal from AMCP will be presented from 11:45 a.m. to 2:45 p.m. April 21 during the AMCP Managed Care & Specialty Pharmacy annual meeting. The poster was authored by a team from Clinical Pharmacy Services, the Office of Clinical Affairs and the Center for Health Policy and Research, all units within UMass Medical School’s Commonwealth Medicine division.
Adherence to Sofosbuvir- and Simeprevir-Based Regimens to Treat Chronic Hepatitis C Virus in a State Medicaid Population
This poster evaluates adherence to sofosbuvir- and simeprevir-based regimens among members within a primary care clinician (PCC) plan of MassHealth, the Massachusetts Medicaid program, and describes reasons for treatment discontinuation. The researchers conclude that the majority of patients maintain a high level of adherence to sofosbuvir/simeprevir regimens if they are members of a Medicaid plan that provides outreach and support.
Pavel Lavitas, PharmD, BCPS, Clinical Pharmacy Services, Commonwealth Medicine
Karen Clements, MPH, ScD, Center for Health Policy and Research, Commonwealth Medicine
Robin E. Clark, PhD, Department of Family Medicine and Community Health, UMass Medical School
Parag S. Kunte, MPH, Center for Health Policy and Research, Commonwealth Medicine
Camilla Graham, MD, MPH, Beth Israel Deaconess Medical Center – Division of Infectious Disease
Kimberly J. Lenz, PharmD, Office of Clinical Affairs, Commonwealth Medicine
Bonnie C. Greenwood, PharmD, BCPS, Clinical Pharmacy Services, Commonwealth Medicine
Paul L. Jeffrey, PharmD, Office of Clinical Affairs, Commonwealth Medicine
Posters developed by members of Clinical Pharmacy Services’ Managed Care Residency Program will be presented from 5:45 to 7:30 p.m. April 20. Managed care pharmacists, a physician and an epidemiologist co-authored the posters with residents.
Evaluating the Impact of a Prescriber Outreach Program on the Co-prescribing of Opioids, Benzodiazepines, Gabapentin and Stimulants in a Medicaid Population
In recent years, there has been an increase in co-prescribing opioids with benzodiazepines, gabapentin and stimulants for MassHealth members. There are known health risks associated with prescribing opioids and benzodiazepines with or without gabapentin, but little is known about the danger of adding stimulants to this drug regimen. This presentation evaluates the impact of a prescriber outreach program on prescribing patterns for patients receiving this combination of medications.
Briana L. Santaniello, PharmD, MBA, Clinical Pharmacy Services, Commonwealth Medicine
Tyson Thompson, PharmD, Clinical Pharmacy Services, Commonwealth Medicine
Thomas C. Pomfret, PharmD, MPH, BCPS, Clinical Pharmacy Services, Commonwealth Medicine
Caroline J. Alper, MD, Clinical Pharmacy Services, Commonwealth Medicine
Kimberly Lenz, PharmD, Office of Clinical Affairs, Commonwealth Medicine
Donna Faber, PharmD, BCPS, Clinical Pharmacy Services, Commonwealth Medicine
Mark Tesell, PharmD, BCPS, Clinical Pharmacy Services, Commonwealth Medicine
Neha Kashalikar, PharmD, Clinical Pharmacy Services, Commonwealth Medicine
Payal N. Kotadiya, PharmD, BCPS, Clinical Pharmacy Services, Commonwealth Medicine
Karen Clements, MPH, ScD, Center for Health Policy and Research, Commonwealth Medicine
Nicole M. Trask, PharmD, Clinical Pharmacy Services, Commonwealth Medicine
Paul L. Jeffrey, PharmD, Office of Clinical Affairs, Commonwealth Medicine
The Impact of a Controlled Substance Act Schedule Change on the Utilization of Hydrocodone Combination Products in a Medicaid Population
The U.S. Department of Health and Human Services and the U.S. Drug Enforcement Administration (DEA) recently analyzed hydrocodone combination products (HCP) and reaffirmed their high potential for abuse. In October 2014, the drugs were reclassified in the DEA schedule of controlled substances in recognition of this high level of risk. This poster evaluates the effect of the schedule change on claims for HCPs in the MassHealth fee-for-service and PCC plan population.
Stephanie Tran, PharmD, Clinical Pharmacy Services, Commonwealth Medicine
Pavel Lavitas, PharmD, BCPS, Clinical Pharmacy Services, Commonwealth Medicine
Karen Stevens, PharmD, Clinical Pharmacy Services, Commonwealth Medicine
Bonnie C. Greenwood, PharmD, BCPS, Clinical Pharmacy Services, Commonwealth Medicine
Karen Clements, MPH, ScD, Center for Health Policy and Research, Commonwealth Medicine
Caroline J. Alper, MD, Clinical Pharmacy Services, Commonwealth Medicine
Kimberly Lenz, PharmD, Office of Clinical Affairs, Commonwealth Medicine
Mylissa Price, MPH, RPh, Clinical Pharmacy Services, Commonwealth Medicine
Tasmina Hydery, PharmD, MBA, Clinical Pharmacy Services, Commonwealth Medicine
Mito Takeshita, PharmD, Clinical Pharmacy Services, Commonwealth Medicine
Rachel Bacon, PharmD, Clinical Pharmacy Services, Commonwealth Medicine
Justin P. Peristere, RPh, Clinical Pharmacy Services, Commonwealth Medicine
Paul L. Jeffrey, PharmD, Office of Clinical Affairs, Commonwealth Medicine